Baidu
map

Hypertension:睾酮通过上调miR-22抑制雌激素信号

2017-02-14 xing.T MedSci原创

该研究的结果揭示了在人胎盘中miR-22调节雄激素和雌激素平衡生产的潜在机制,并从调节内分泌的角度为子痫前期的发病机制提供了新的见解。

子痫前期是一个多系统综合征,主要发生在人类妊娠中期到后期,是导致孕产妇和围产儿发病和死亡的主要原因。患者通常表现为循环中睾酮水平升高和雌二醇水平下降,但其机制仍不清楚。揭示子痫前期患者睾酮和雌二醇失衡的调节机制对了解疾病发生原因具有重要价值。

胎盘是妊娠期激素生产的主要来源,近日,心血管权威杂志Hypertension上发表一篇中国学者的研究文章,研究人员在子痫前期患者胎盘中观察到显著升高的17β-HSD3(17β-羟类固醇脱氢酶3)水平以及下调芳香化酶的表达,此酶是负责合成睾酮和雌二醇的关键酶,相比于对照者而言。此外,研究人员还发现子痫前期患者胎盘中microRNA(miR)-22的表达也显著上调。在滋养层细胞系JEG-3细胞中,睾酮可以抑制芳香化酶和雌激素受体α,并且促进miR-22的表达可以导致雌二醇的产生。miR-22可以直接靶向抑制雌激素受体α的表达,从而通过干扰雌激素受体α信号间接降低芳香化酶的表达和雌二醇的生产。此外,抑制miR-22表达可以显著逆转头滋养层细胞中睾酮对雌二醇从头合成的抑制作用。

该研究的结果揭示了在人胎盘中miR-22调节雄激素和雌激素平衡生产的潜在机制,并从调节内分泌的角度为子痫前期的发病机制提供了新的见解。

原始出处:

Xuan Shao, et al. Testosterone Represses Estrogen Signaling by Upregulating miR-22 A Mechanism for Imbalanced Steroid Hormone Production in Preeclampsia. Hypertension. 2017. https://doi.org/10.1161/HYPERTENSIONAHA.116.08468

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930436, encodeId=f67119304365b, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Dec 09 13:05:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989548, encodeId=7cce198954804, content=<a href='/topic/show?id=eebd1186594' target=_blank style='color:#2F92EE;'>#miR-22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11865, encryptionId=eebd1186594, topicName=miR-22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 25 09:05:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038585, encodeId=366a203858538, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jan 20 21:05:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726289, encodeId=58011e26289a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 01 11:05:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501117, encodeId=b89a150111ebc, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Feb 16 01:05:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-12-09 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930436, encodeId=f67119304365b, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Dec 09 13:05:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989548, encodeId=7cce198954804, content=<a href='/topic/show?id=eebd1186594' target=_blank style='color:#2F92EE;'>#miR-22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11865, encryptionId=eebd1186594, topicName=miR-22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 25 09:05:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038585, encodeId=366a203858538, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jan 20 21:05:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726289, encodeId=58011e26289a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 01 11:05:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501117, encodeId=b89a150111ebc, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Feb 16 01:05:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-06-25 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930436, encodeId=f67119304365b, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Dec 09 13:05:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989548, encodeId=7cce198954804, content=<a href='/topic/show?id=eebd1186594' target=_blank style='color:#2F92EE;'>#miR-22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11865, encryptionId=eebd1186594, topicName=miR-22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 25 09:05:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038585, encodeId=366a203858538, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jan 20 21:05:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726289, encodeId=58011e26289a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 01 11:05:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501117, encodeId=b89a150111ebc, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Feb 16 01:05:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930436, encodeId=f67119304365b, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Dec 09 13:05:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989548, encodeId=7cce198954804, content=<a href='/topic/show?id=eebd1186594' target=_blank style='color:#2F92EE;'>#miR-22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11865, encryptionId=eebd1186594, topicName=miR-22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 25 09:05:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038585, encodeId=366a203858538, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jan 20 21:05:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726289, encodeId=58011e26289a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 01 11:05:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501117, encodeId=b89a150111ebc, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Feb 16 01:05:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-08-01 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930436, encodeId=f67119304365b, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Dec 09 13:05:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989548, encodeId=7cce198954804, content=<a href='/topic/show?id=eebd1186594' target=_blank style='color:#2F92EE;'>#miR-22#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11865, encryptionId=eebd1186594, topicName=miR-22)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Jun 25 09:05:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038585, encodeId=366a203858538, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Jan 20 21:05:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726289, encodeId=58011e26289a1, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 01 11:05:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501117, encodeId=b89a150111ebc, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Feb 16 01:05:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]

相关资讯

睾酮替代治疗,让男性重振雄风!

睾酮是人体主要的循环雄激素,与性别分化、生长以及维持生殖功能、第二性征和性欲有关。男性一旦进入三十岁之后,睾酮水平便开始下降,正常情况下每年下降约1%左右。这么重要的激素,缺了这么办?缺啥补啥呗!——在美国,2001-2011年期间,≥40岁男性中,睾酮替代疗法使用者增加了3倍多。不过,睾酮替代治疗并不是随便谁谁谁想用就能用的——美国食品和药物管理局(FDA)要求所有睾酮产品制造商一定要在标签

J Clin Endocrinol Metab:孕激素和睾酮联合注射可有效用于男性避孕

目前,仍未有一种安全有效的可逆性男性避孕方法。本研究旨在评估联用孕激素和睾酮注射抑制精子发生和避孕保护的效果。 采用前瞻性多中心研究设计,在十个研究中心,纳入18-45岁的健康男性,以及其18-38岁的女性伴侣,均无生育问题。 对男性参与者进行肌内注射庚酸炔诺酮200毫克和1000毫克睾酮,每8周给药一次。然后通过精液分析精子发生的抑制作用,通过妊娠率来评估避孕保护效果。 结果,

盘点:除了影响性功能,睾酮还会影响糖尿病的发生

睾酮是人体主要的循环雄激素,与性别分化、生长以及维持生殖功能、第二性征和性欲有关。男性一旦进入三十岁之后,睾酮水平便开始下降,正常情况下每年下降约1%左右。这里梅斯小编整理了关于睾酮的一些研究供大家了解。【1】低睾酮水平可能是2型糖尿病的危险标志近期发表在The Journal of Clinical Endocrinology & Metabolism的研究称,睾酮水平低可能是2型糖

BMJ:睾酮治疗与静脉血栓栓塞风险增加有关

由此可见,开始睾酮治疗与静脉血栓栓塞的风险增加有关,并在六个月内达到高峰,此后下降。

天哪!真的可以从手指长度来看大脑功能

近日,据发表于Behavioural Brain Research的一项新的研究探究了手指长度与大脑工作之间的关联。总所周知,子宫内睾酮的水平可影响胎儿成年后的手指长度。与无名指相比,食指长度较短说明其胎儿期其母体子宫内的睾酮水平较高,而食指长度较长说明睾酮水平较低。研究共纳入了42名女性,测量其手指长度,对21名女性给予一滴睾酮,另外21名女性作为对照组给予安慰剂。之后所有研究对象处理多种心理问

BMC MED:睾酮治疗会对男性节食减肥产生什么影响?

对于节食减肥的肥胖男性,如果加入睾酮治疗,会对减肥效果产生什么影响呢? 我们在一个三级转诊中心进行了一项随机双盲、平行、安慰剂对照试验。共纳入了100名肥胖男性(BMI ≥ 30 kg/m2),总睾酮水平低于12 nmol/L的,中位数年龄53年(四分位距为47–60),接受长达10周的极低能量饮食(VLED),随后体重维持46周。将这些患者随机分到每周肌肉注射十一酸睾酮,进行10周(n=4

Baidu
map
Baidu
map
Baidu
map